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fibrillation (AF) pathophysiology, pharmacological, ablative and
surgical treatments are still suboptimal, so AF remains a challenge
of contemporary cardiology [1–4]. Although there are many well-
established predisposing conditions and risk factors for AF, there
is still a clear unmet need to expand knowledge of new mecha-
nisms and treatment strategies to reduce morbidity and mortality
in AF patients.
Beyond other risk factors, the Western diet and additional life-
style-component have been linked to the occurrence and progres-
sion of AF. Growing evidence has demonstrated that gut
microbiota related mechanisms play a critical role in many cardio-
vascular diseases including AF [5]. The most recent and under-
examined agent significantly affecting the process of initiation
and progression of AF is trimethylamine N-oxide (TMAO), a micro-
bial-derived metabolite generated in a two-step process including
enzymatic transformation of dietary choline or L-carnitine into
TMA and its further oxidization in the liver by flavin-containing
monooxygenase (FMO) [6].
Several pathological mechanisms of TMAO in AF have been
reported [5–10]. TMAO may promote AF by modulating the cardiac
autonomic nervous system [5] and cellular osmolarity [7], promot-
ing inflammation [6], causing cardiac fibrosis [8], increasing
thrombosis via platelet activation [9], and promoting coronary
atherosclerosis [10].
TMAO may also have some prognostic value as a biomarker.
Recently, elevated plasma levels of TMAO have been proven to
be a strong predictor of AF development among patients with
and without suspected stable angina [7], ischemic stroke and car-
diac thrombus formation among patients with AF [11] and there is
a proven correlation between TMAO levels and CHA2DS2-VASc
score [12].
The precise mechanisms linking AF and TMAO in humans are
still poorly understood, and most studies have focused on the pre-
dictive value of TMAO for first AF incidence. In this context, Büttner
et al. [13], detected the levels of TMAO in 45 AF patients and com-
pared them to those of 20 sinus rhythm controls (nSR), both before
and after catheter ablation. The authors did not observe a signifi-
cant difference in the levels of TMAO between AF patients and
nSR, and detected no correlation between the levels of TMAO and
AF progression phenotypes. Despite the overall increase during
the 12–18-month follow-up, the TMAO levels increased indepen-
dently from the success of the catheter ablation procedure, defined
as restoration of nSR. These findings are inconsistent with themany positive correlations between TMAO and AF in the literature,
likely because the study population was rather small and under-
powered to detect a positive correlation between AF and TMAO
levels. In addition, subclinical cardiovascular or renal disease might
be present in the nSR group, also biasing the results. Finally, lack of
detailed and longitudinal information on dietary intakes, enabling
to estimate daily intake of total carnitine, choline, betaine and
sodium could lead to an underestimation of true TMAO-AF rela-
tionship [14].
Plasma TMAO levels may show wide inter- and intra-individual
variations, which could be influenced by several factors (Fig. 1). A
lack of adjustment for these covariables might mask potential dif-
ferences between TMAO levels, AF-type and AF-treatment. TMAO
concentration increases with age, estrogens (while testosterone
acts as suppressor) and levels of cholic acid that induce FMO
expression [15]. Noteworthy, the gut microbiota composition and
its metabolites profile are highly specific to the host and are mod-
ulated by many extrinsic (diet, lifestyle, and medication) and
intrinsic (host genetics, immune, and metabolic regulations) fac-
tors [16]. More than 15% of gut microbiota community exhibits
diurnal oscillations that are influenced by feeding rhythms [17]
and sleep patterns [18]. Diet is thought to explain over 20% of
the gut microbiota structural variations in the human, indicating
the potential for therapeutic dietary strategies to manipulate
microbial diversity, composition, and stability. Recently, high-fat,
high-protein or rich in indigestible starch diets were shown to
increase plasma TMAO levels [15]. There is also evidence that
TMAO is a key regulator not only of lipid metabolism, but also of
white adipose tissue formation [19]. Renal clearance plays a major
and critical role in plasma TMAO levels, with a reduction in
glomerular filtration rate increasing TMAO levels [20]. Further, it
is important to bear in mind that medications such a methimazole,
alosetron, duloxetine, clozapine, pirfenidone, which inhibit FMO,
along with meldonium, resveratrol, 3,3-dimethyldimethyl-1-buta-
nol, enalapril may all cause a reduction in the TMAO levels [15].
Several experimental studies suggest a possible involvement of
TMAO in the etiology of cardiovascular disease and neurological
disorders [15]. The close link between TMAO and inflammatory
burden suggests that inflammation could mediate some of the
deleterious effects of TMAO. However, the precise effects of cardio-
vascular medications on the levels of TMAO need further investiga-
tion. Finally, the assessment of TMAO plasma levels likely
represent a composite consequence of diet and lifestyle compo-
nents, which may result in significant temporal fluctuations.
Fig. 1. Schematic representation of the impact of various intrinsic and extrinsic factors on the trimethylamine N-oxide levels.
2 Editorial / IJC Heart & Vasculature 29 (2020) 100581Therefore, a more longitudinal assessment of TMAO together with
a diet and lifestyle diary rather than one spot-assessment may be
required to better characterize the relationship to AF presentation
and its progression.
In conclusion, TMAO appears to constitute a putative bio- and
lifestyle-marker and a predictor of new-onset AF, its progression
and the AF-associated ischemic events beyond traditional risk fac-
tors. Future large-scale studies comparing TMAO levels in patients
with different types of AFs (paroxysmal/persistent/permanent) and
TMAO fluctuations related to rhythm control strategies (cardiover-
sion/catheter ablation) are needed to prove and validate whether
TMAO and other gut microbiota-derived metabolites might repre-
sent modifiable risk factors of AF.
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